Browse > Article
http://dx.doi.org/10.3742/OPEM.2010.10.4.239

Coenzyme Q10: a progress towards the treatment of neurodegenerative disease  

Kumar, Peeyush (Institute of Pharmaceutical Sciences, Guru Ghasidas vishwavidyalaya)
Kumar, Pramod (Institute of Pharmaceutical Sciences, Guru Ghasidas vishwavidyalaya)
Ram, Alpana (Institute of Pharmaceutical Sciences, Guru Ghasidas vishwavidyalaya)
Kuma, Mithilesh (Depatment of Pharmaceutical Technology, Jadavpur University)
Kumar, Rajeev (Depatment of Pharmaceutical Technology, Jadavpur University)
Publication Information
Advances in Traditional Medicine / v.10, no.4, 2010 , pp. 239-253 More about this Journal
Abstract
Coenzyme $Q_{10}$ ($CoQ_{10}$, or ubiquinone) is an electron carrier of the mitochondrial respiratory chain (electron transport chain) with antioxidant properties. In view of the involvement of $CoQ_{10}$ in oxidative phosphorylation and cellular antioxidant protection a deficiency in this quinone would be expected to contribute to disease pathophysiology by causing a failure in energy metabolism and antioxidant status. Indeed, a deficit in $CoQ_{10}$ status has been determined in a number of neuromuscular and neurodegenerative disorders. Primary disorders of $CoQ_{10}$ biosynthesis are potentially treatable conditions and therefore a high degree of clinical awareness about this condition is essential. A secondary loss of $CoQ_{10}$ status following HMG-CoA reductase inhibitor (statins) treatment has been implicated in the pathophysiology of the myotoxicity associated with this pharmacotherapy. $CoQ_{10}$ and its analogue, idebenone, have been widely used in the treatment of neurodegenerative and neuromuscular disorders. These compounds could potentially play a role in the treatment of mitochondrial disorders, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of $CoQ_{10}$, as well as the rationale and the role in clinical practice of $CoQ_{10}$ supplementation in different neurological diseases, from primary $CoQ_{10}$ deficiency to neurodegenerative disorders. These will help in future for treatment of patients suffering from neurodegenerative disease.
Keywords
Coenzyme $Q_{10}$; Antioxidant; Ageing; Oxidative stress; Neurodegenerative diseases;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’regan JP, Deng HX, Rahmani Z, Krizus A, Mckenna-Yasek, D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin J. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362, 59-62.   DOI   ScienceOn
2 Rowland LP, Shneider NA. (2001) Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688-1700.   DOI   ScienceOn
3 Rozen T, Oshinsky M, Gebeline C, Bradley K, Young W, Shechter A, Silberstein S. (2002) Open label trial of coenzyme $Q_{10}$ as a migraine preventive. Cephalalgia. 22,137–41.   DOI   ScienceOn
4 Sandor PS. (2005) Efficacy of coenzyme $Q_{10}$ in migraine prophylaxis: A randomized controlled trial. Neurology. 64, 713-715.   DOI   ScienceOn
5 Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. (1990) Anatomic disease specificity of NADH CoQ1 redutase (complex I) deficiency in Parkinson’s disease. J. Neurochem. 55, 2142-2145.   DOI
6 Schoepp G. (1999) Is coenzyme $Q_{10}$ (ubiquinone) effective for the treatment of heart failure Pharm. Pract. 13, 31-32.
7 Shinde S, Patil N, Tendolkar A. (2005) Coenzyme $Q_{10}$: a review of essential functions. Internet J. Nutr. Wellness, v.1, n.2.
8 Murata T, Ohtsuka C, Terayama Y. (2008) Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 267, 66-69.   DOI   ScienceOn
9 Muta-Takada K, Terada T, Yamanishi H, Ashida Y, Inomata S, Nishiyama T, Amano S, (2009) Coenzyme $Q_{10}$ protects against oxidative stress-induced cell death and enhances the synthesis of basement membrane components in dermal and epidermal cells. Biofactors. 35, 435-41.   DOI   ScienceOn
10 Naught MC, Olanow CW. (2003) Proteolytic stress: a unifying concept for the etiopathogenesisof Parkinson’s disease. Ann. Neurol. 53, 3-86.   DOI   ScienceOn
11 Nohl H, Kozlov AV, Staniek K, Gille L. (2001) The multiple functions of coenzyme Q. Bio. org. Chem. 29, 1-13.
12 Parker JR, Boyson SJ, Parks JK. (1998) Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. An. Neurol. 26, 719-723.
13 Pepping J. (1999) Coenzyme $Q_{10}$. Am. J. Health Syst. Pharm. 56, 519-521.
14 Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Blysma F, Coyle JT, Mchugh PR, Folstein SE. (1995) Trial of D-a-tocopherol in Huntington’s disease. Am. J. Psychiat. 152, 1771-1775.   DOI
15 Quiles JL, Ochoa JJ, Huertas JR, Mataix J. (2004) Coenzyme Q supplementation protects from agerelated DNA double-strand breaks and increases lifespan in rats fed on a PUFA-rich diet. Exp Gerontol. 39, 189-94.   DOI   ScienceOn
16 Quinn PJ, Fabisiak JP, Kagan VE. (1999) Expansion of antioxidant function of vitamin E by coenzyme Q. Bio. Factors. 9, 149-154.
17 Quinzii CM, Dimauro S. (2007a) Hirano, M. Human coenzyme $Q_{10}$ deficiency. Neurochem. Res. 32, 723- 727.   DOI
18 Quinzii CM, Hirano M, Dimauro S. (2007b) Co$Q_{10}$ deficiency diseases in adults. Mitochondrion. 7, 122-126.   DOI   ScienceOn
19 Langsjoen PH, Langsjoen AM. (1999) Overview of the use of Co$Q_{10}$ in cardiovascular disease, Biofactors. 9, 273-284.   DOI
20 Lenaz G, Bovina C, Formiggini G, Castelli GP. (1999) Mitochondria, oxidative stress, and antioxidant defences. Acta. Biochim. Pol. 46.
21 Littarru GP. (2006) Coenzyme $Q_{10}$: from biochemistry to medicine. The Metabolic Approach Forum. Avaiable at: http://www.st-hs.com. Accessed on 10 oct.2008.
22 Littarru GP, Tiano L. (2010) Clinical aspects of coenzyme $Q_{10}$: an update. Nutrition. Mar. 26, 250- 254.   DOI   ScienceOn
23 Mason P. (2005) Potential uses for coenzyme $Q_{10}$. Pharm. J. 275, 379-382.
24 Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. (2010) Coenzyme $Q_{10}$ in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 1, 111-21.
25 Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. (2009) Lower plasma Coenzyme $Q_{10}$ in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol. Lett. 4, 462-469.
26 Matthews RT, Yang S, Browne S, Baik M, Beal MF. (1998a) Coenzyme $Q_{10}$ administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. 95, 8892-8897.   DOI   ScienceOn
27 Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. (1998b) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington’s disease. J. Neurosci. 18, 156-163.
28 Muller T, Buttner T, Gholipour AF, Kuhn W (2003) Coenzyme $Q_{10}$ supplementation provides mild symptomatic benefit in patients with Parkinson´s disease. Neurosci. Lett. 341, 201-204.   DOI   ScienceOn
29 Kasparova S, Sumbalova Z, Bystricky P, Kucharska J, Liptaj T, Mlynarik V, Gvozdjakova A. (2006) Effect of coenzyme $Q_{10}$ and vitam E on brain energy metabolism in the animal model of Huntington´s disease. Neurochem. Int. 48, 93-99.   DOI   ScienceOn
30 Kawamoto EM, Munhoz CD, Glezer I, Bahia VS, Caramelli P, Nitrini R, Gorjao R, Curi R, Scavone C, Marcourakis T. (2005) Oxidative stress in platelets and erythrocytes in aging and Alzheimer’s disease. Neurobiol. Aging. 26, 857-864.   DOI   ScienceOn
31 Kitano M, Hosoe K, Fukutomi N, Hidaka T, Ohta R, Yamakage K, Hara T. (2006) Evaluation of the mutagenic potential of ubidecarenone using three short-term assays. Food Chem. Toxicol. 44, 364-370.   DOI   ScienceOn
32 Koryagin AS, Krylova EV, Lukyanova LD. (2002) “Effect of Ubiquinone-10 on the Blood System in Rats Exposed to Radiation”. Bulletin of Experimental Biology and Medicine, 562-564.
33 Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. (1997) Energy metabolism defects in Hiuntington’s disease and effects of coenzyme $Q_{10}$. Ann. Neurol. 41, 160-165.   DOI   ScienceOn
34 Kwong L, Kamzalov S, Rebrin I, Bayne ACV, Jana CK, Morris P, Forster MJ, Sohal RS. (2002) Effects of coenzyme $Q_{10}$ administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Rad. Biol. Med. 33, 627-638.   DOI   ScienceOn
35 Langsjoen PH, Klinische W. (1993) Expansion of antioxidant function of vitamin E by coenzyme Q Clinical Investigator. 71, 145-149.
36 Langston JW, Ballard P, Tetrud JW, Irwin I. (1983) Chronic Parkinsonism in humans due to a product of mepeidine-analog synthesis. Science. 219, 979-980.   DOI
37 Langsjoen PH, Langsjoen AM. (2003) The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme $Q_{10}$: A review of animal and human publications. Biofactors. 18, 101-111.   DOI
38 Hebert LE, Beckett LA, Scherr PA, Evans DA. (2000) Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. lzheimer Dis. Assoc. Disord. 15, 169-173.
39 Hidaka T, Fujii K, Funahashi I, Fukutomi N, Hosoe K. (2008) Safety assessment of coenzyme $Q_{10}$ (Co$Q_{10}$). Biofactors. 32, 199-208.   DOI
40 Hollingsworth Z, Shoulson I, Lazzarini A, Falek A, Koroshetz W, Sax D, Bird E. (1993) Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat. Genet. 4, 387-392.   DOI   ScienceOn
41 Hughes K, Lee BL, Feng X, Lee J, Ong CN. (2002) Coenzyme $Q_{10}$ and differences in coronary heart disease risk in Asian Indians and Chinese. Free Rad. Biol. Med. 32, 132-138.   DOI   ScienceOn
42 Ishrat T, Khan MB, Hoda MD, Yousuf S, Ahmad M, Ansari MA, Ahmad AS, Islam F. (2006) Coenzyme $Q_{10}$ modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav. Brain Res. 171, 9-16.   DOI   ScienceOn
43 Ishii N, Senoo-Matsuda N, Miyake K, Yasuda K, Ishii T, Hartman PS. (2004) “Coenzyme $Q_{10}$ can prolong C. elegans lifespan by lowering oxidative stress”. Mech Ageing Dev. 125, 41-46.   DOI   ScienceOn
44 Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, Macdonald M, Rosen BR, Beal MF, Koroshetz WJH. (1998) NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology. 50, 1357-1365.   DOI   ScienceOn
45 Jenner P. (2003) Oxidative stress in Parkinson’s disease. Ann. Neurol. 53, suppl. 26-38.   DOI   ScienceOn
46 Kalen A, Appelkvist EL, Dallner G. (1989) Age related changes in the lipid composition of rat and human tissue. Lipids. 24, 579-584.   DOI
47 Kamzalov S, Sumien N, Forster MJ, Sohal RS. (2003) Coenzyme Q intake elevates the mitochondrial and tissue levels of coenzyme Q and $\alpha$-tocopherol in young mice. J. Nutr. 133, 175-3180.
48 Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, Macgarvey U, Kowall NW, Brown JR, Beal MF. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064-2074.
49 Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. (2002) Therapeutic effects of coenzyme $Q_{10}$ and remacemide in transgenic mouse models of Huntington’s disease. J. Neurosci. 22, 1592-1599.
50 Floyd RA. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236-245.   DOI
51 Francis PT, Palmer AM, Snape M, Wilcock GK. (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 66, 137-147.   DOI
52 Fu X, Ji R, Dam J. (2010) Antifatigue effect of coenzyme $Q_{10}$ in mice., J. Med. Food. 1, 211-15.
53 Galpern WR, Cudkowicz ME. (2007) Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion. 7, 146-53.   DOI   ScienceOn
54 Gary EG. (2005) Hsueh-Meei, H. Oxidative stress in Alzheimer’s disease. Neurobiol. Aging. 26, 575-578.   DOI   ScienceOn
55 Goldberg YP, Telenius H, Hayden MR. (1994) The molecular genetics of Huntington’s disease. Curr. Opin. Neurol. 7, 325-32.   DOI
56 Gokbel H, Gul I, Belviranl M, Okudan N. (2010) The effects of coenzyme $Q_{10}$ supplementation on performance during repeated bouts of supramaximal exercise in sedentary men. J. Strength Cond. Res. 1, 97-102.
57 Halliwell B, Ann NY. (2002) Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Acad. Sci. 962, 182-194.   DOI   ScienceOn
58 Cutler NR, Sramek JJ. (2001) Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog. Neuro- Psychopharmacol. Biol. Psychiat. 25, 27-57.   DOI   ScienceOn
59 Dawson TM, Dawson VL. (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science. 302, 819-822.   DOI   ScienceOn
60 De Lau L, Breteler MB. (2006) Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525-535, 2006.   DOI   ScienceOn
61 Donald MC, Sohal SR, Forster MJ. (2005) Concurrent administration of coenzyme $Q_{10}$ and alpha-tocopherol improves learning in aged mice. Free Rad. Biol. Med. 38, 729-73.   DOI   ScienceOn
62 Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, Gray J, Conneally P, Young A, Penney J. (1993) Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat. Genet. 4, 387-392.   DOI   ScienceOn
63 Dutton PL, Ohnishi T, Darrouzet E, Leonard MA, Sharp RE, Cibney BR. (2000). Coenzyme Q oxidation reduction reactions in mitochondrial electron transport. CRC Press, Boca. Raton. 65-82.
64 Ernster L, Dallner G. (1995). Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta. 1271, 195-204.   DOI   ScienceOn
65 Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert E, Hennekens CH, Taulor JO. (1989) Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. J. Am. Med. Assoc. 262, 2551-2556.   DOI
66 Farout L, Friguet B. (2006) Proteasome function in aging and oxidative stress implications in protein maintenance failure. Antioxid. Redox. Signal. 8, 205- 216.   DOI   ScienceOn
67 Feigin A, Kieburtz K, Como P, Hickey C, Claude K. (1996) Assessment of coenzyme $Q_{10}$ tolerability in Huntington’s disease. Mov. Disord. 11, 321-323.   DOI   ScienceOn
68 Beyer RE, Burnett BA, Cartwright KJ, Edington DW. (1985) Tissue coenzyme Q (ubiquinone) and protein concentration over the life span of the laboratory rat. Mech. Aging Dev. 32, 267-281.   DOI   ScienceOn
69 Bogdanov M, Brown JR, RH, Matson W, Smart R, Hayden D, O' Donnell H, Flint M, Cudkowicz M. (2000) Increased oxidative damage to DNA in ALS patients. Free Rad. Biol. Med. 29, 652-658.   DOI   ScienceOn
70 Bonakdar RA, Guarneri E. (2005) Coenzyme $Q_{10}$. Am. Fam. Physician. 72, 1065-1070.
71 Browne SE, Ferranti RJ, Beal MF. (1999) Oxidative stress in Huntington’s disease. Brain Pathol. 9, 147- 163.
72 Bustus F, Molina JA, Jimenez-Jimenez FJ, Garcia- RedondoA, Gomez-Escalonilla C, Porta-Etessam J, Berbel A, Zurdo M, Barcenilla B, Parrilla G, Enriquez-De-Salamanca R, Arenas J. (2000) Serum levels of coenzyme $Q_{10}$ in patients with Alzheimer’s disease. J. Neural. Transm. 107, 233-239.   DOI
73 Butterfield DA. (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain. Brain Res. 1000, 1-7.   DOI   ScienceOn
74 Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. (2006) Seminar on choreas. Lancet Neurol. 5, 589-602.   DOI   ScienceOn
75 Coles L, Harris S. (1996) Coenzyme Q-10 and Lifespan Extension. Advances in Anti-Aging Medicine. 1, 205- 215.
76 Coyle JT, Puttafarcken P. (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science. 262, 689-695.
77 Crane FL, Hatefi Y, Lester RL, Widmer C. (1957) Isolation of a quinone from beef heart mitochondria. Biochem. Biophys. Acta. 25, 220-221.   DOI
78 Crane F. (2001) Biochemical functions of coenzyme $Q_{10}$. J. Am. Coll. Nutr. 20, 591-598.   DOI
79 Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. (1994) Italian multicenter study on the safety and efficacy of coenzyme $Q_{10}$ as adjunctive therapy in heart failure. Molec. Aspects. Meds. Suppl. 15, 287-294.   DOI   ScienceOn
80 Beal MF. (2005) Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58, 495- 505.   DOI   ScienceOn
81 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ,Martin JB. (1988) Systemic approaches to modifying quinolinic acid striatal lesions in rats. J. Neurosci. 10, 3901-3908.
82 Beal MF, Henshaw R, Jenkins BG, Rosen BR, Schulz JB.(1994) Coenzyme $Q_{10}$ and nicotinamide blocks striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 36, 882-888.   DOI   ScienceOn
83 Beal MF. (1995) Aging, energy and oxidative stress in neurodege-nerative diseases. Ann. Neurol. 38, 357- 366.   DOI   ScienceOn
84 Beal MF, Matthews RT. (1997a) Coenzyme $Q_{10}$ in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol. Aspects Med.18, 169-179.   DOI   ScienceOn
85 Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. (1997b) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42, 644-654.   DOI   ScienceOn
86 Beal MF. (1999a) Mitochondria, NO and neurodegeneration. Biochem. Soc. Symp. 66, 43-54.   DOI
87 Beal MF. (1999b) Coenzyme $Q_{10}$ administration and its potential for treatment of neurodegenerative diseases. Biofactors. 9, 261-266.
88 Benecke R, Strumper P, Weiss H. (1993) Electron transfer complexes I and IV of platelets are abnormal in Parkinson’s disease but normal in Parkinson-plus syndromes. Brain. 116, 1451-1463.   DOI   ScienceOn
89 Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal, AK, Islam F. (2005) Ginkgo biloba affords dosedependent protection against 6-hydroxydopamineinduced Parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J. Neurochem. 93, 94-104.   DOI   ScienceOn
90 Andrich J, Saft C, Gerlach M, Schneider B, Arz A, Kuhn W, Muller T. (2004). Coenzyme $Q_{10}$ serum levels in Huntington’s disease. J. Neural. Transm. Suppl. 68, 111-116.
91 Ansari MA, Ahmad AS, Ahmad M, Salim S, Yousuf S, Ishrat T, Islam F. (2004) Selenium protects cerebral ischemia in rat brain mitochondria. Biol. Trace Elem. Res. 101, 73-86.   DOI   ScienceOn
92 Arroyo A, Kagan VE, Tyurin VA, Burgess JR, De Cabo R, Navas P, Villalba JM. (2000) NADH and NADPH-dependent reduction of coenzyme Q at the plasma membrane. Antioxid. Redox. Signal. 2, 251-262.   DOI   ScienceOn
93 Spindler M, Beal MF, Henchcliffe C. (2009) Department of Neurology, Coenzyme $Q_{10}$ effects in neurodegenerative disease. Neuropsychiatr Dis. Treat. 5, 597-610.
94 Stocker R, Pollicino C, Gay CA. (1991) Neither plasma coenzyme concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective casecontrol study from the LIPID study.
95 Tran MT, Mitchell TM, Kennedy DT, Giles JT. (2001) Role of coenzyme $Q_{10}$ in chronic heart failure, angina, and hypertension. Pharmacother. 21, 797-806.   DOI   ScienceOn
96 Thomas SR, Stocker R. (2000) Mechanisms of antioxidant action of ubiquinol-10 for low density lipoprotein. pp 131-150 in Coenzyme Q: Molecular mechanisms in health and disease. 9, 131-150.
97 Traynor BJ, Bruijn L, Conwit R, Beal FO, Neill G, Fagan SC, Cudkowicz ME. (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 67, 20-27.   DOI
98 Zhang Y, Aberg F, Appelkvist EL, Dallner G, Ernster L. (1995) Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 125, 446-453.
99 Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R. (2002) Effects of coenzyme $Q_{10}$ in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol, 59, 1541-1550.   DOI   ScienceOn
100 Shults CW, Haas RH, Beal MF. (1999) A possible role of coenzyme $Q_{10}$ in the etiology and treatment of Parkinson’s disease. BioFactors, 9, 267-272.   DOI
101 Soderberg M, Edlund JA, Alafuzoff I, Kristensson K, Dallner G. (1992) Lipid composition in different regions of the brain in Alzheimer’s disease/senile dementia of Alzheimer’s type. J. Neurochem. 59, 1646-1653.   DOI   ScienceOn
102 Soja AM, Mortensen SA. (1997) Treatment of congestive heart failure with coenzyme $Q_{10}$ illuminated by meta-analyses of clinical trials. Mol Aspects Med 18, 159-168.   DOI   ScienceOn
103 Sohal RS. (2004) Coenzyme Q and vitamin E interactions. Methods Enzymol. 378, 146-151.   DOI   ScienceOn
104 Sohal RS, Dubey A. (1994) Mitochondrial oxidative damage, hidrogen peroxide release and aging. Free Rad. Biol. Med. 16, 621-626.   DOI   ScienceOn
105 Sohal RS, Forster MJ. (1997) Coenzyme Q, oxidative stress and aging. Mitochondrion. 7, suppl.103-111.
106 Sohmiya M, Tanaka M, Tak NW, Yanagisawa M, Tanino Y, Suzuki Y, Okamoto K, Yamamoto Y. Redox status of plasma coenzyme $Q_{10}$ indicates elevated systemic oxidative stress in Parkinson's disease. J. Neurol. Sci. 223, 161-166.
107 Somayajulu M, Mccarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S. (2005) Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme $Q_{10}$. Neurobiol. Dis. 18, 618-627.   DOI   ScienceOn
108 Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. (2002) Amyotrophic lateral sclerosis in Olmsted County, Minnesota. Neurology, 59, 280-282.   DOI   ScienceOn
109 Rauscher FM, Sanders RA, Watkins JB. (2001) Effects of coenzyme $Q_{10}$ treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. Biochem. Mol. Toxicol. 15, 41-46.   DOI   ScienceOn
110 Rebrin I, Sohal RS. (2004) Distribution and measurement of coenzyme Q. Methods Enzymol. 378, 146-151.   DOI   ScienceOn
111 Rosenfeldt FL, Haas SJ, Krum H, Hadjm AK, Leong JY, Watts GF. (2007). Coenzyme $Q_{10}$ in the treatment of hypertension: a meta-analysis of the clinical trials. J. Human Hypertension. 21, 297-306.   DOI